10.75
0.22%
-0.0247
Immatics N.V stock is currently priced at $10.75, with a 24-hour trading volume of 26,767.
It has seen a -0.22% decreased in the last 24 hours and a +1.57% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $10.90 pivot point. If it approaches the $10.61 support level, significant changes may occur.
Previous Close:
$10.77
Open:
$10.81
24h Volume:
26,767
Market Cap:
$1.11B
Revenue:
$58.49M
Net Income/Loss:
$-105.04M
P/E Ratio:
-9.0624
EPS:
-1.1857
Net Cash Flow:
$-13.78M
1W Performance:
+7.68%
1M Performance:
+1.57%
6M Performance:
+11.59%
1Y Performance:
+6.40%
Immatics N.V Stock (IMTX) Company Profile
Name
Immatics N.V
Sector
Industry
Phone
49 7071 5397 0
Address
Paul-Ehrlich-Str. 15, Tuebingen
Immatics N.V Stock (IMTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-31-23 | Initiated | Mizuho | Buy |
Mar-24-23 | Initiated | Bryan Garnier | Buy |
Nov-20-20 | Initiated | BofA Securities | Buy |
Sep-22-20 | Initiated | Goldman | Buy |
Jul-27-20 | Initiated | SVB Leerink | Outperform |
Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N.V Stock (IMTX) Latest News
Immatics Announces Pricing of $175 Million Public Offering
GlobeNewswire Inc.
Immatics Announces Proposed Public Offering
GlobeNewswire Inc.
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
Zacks Investment Research
Immatics Announces Third Quarter 2023 Financial Results and Business Update
GlobeNewswire Inc.
Immatics (IMTX) Moves 23.2% Higher: Will This Strength Last?
Zacks Investment Research
Immatics N.V Stock (IMTX) Financials Data
Immatics N.V (IMTX) Revenue 2024
IMTX reported a revenue (TTM) of $58.49 million for the quarter ending December 31, 2023, a -68.80% decline year-over-year.
Immatics N.V (IMTX) Net Income 2024
IMTX net income (TTM) was -$105.04 million for the quarter ending December 31, 2023, a -325.36% decrease year-over-year.
Immatics N.V (IMTX) Cash Flow 2024
IMTX recorded a free cash flow (TTM) of -$13.78 million for the quarter ending December 31, 2023, a -113.91% decrease year-over-year.
Immatics N.V (IMTX) Earnings per Share 2024
IMTX earnings per share (TTM) was -$1.2997 for the quarter ending December 31, 2023, a -279.76% decline year-over-year.
About Immatics N.V
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tübingen, Germany.
Cap:
|
Volume (24h):